Letter to Shareholders

Published: March 9th, 2023 
Mission Viejo and Irvine, Calif., March 9th,  2023 (PRDistribution) — 
Dear Stakeholders,
Nearly our entire portfolio of startups made great strides in progress in 2022 and are off to great start in early 2023.
Here is a link to the Executive Summary of our 2022 Annual Report > https://lventuresnew.wpenginepowered.com/wp-content/uploads/2023/02/Аnnual-Report_2022.pdf   (note we are changing photos and making some adds). 
We are highly focused on moving to commercialization and exit opportunities our single focused platform bioelectric stimulator technology platform.  We are no primarily a one product company with a single bioelectric stimulator platform.  This same stimulator circuit board design has been developed into three size configurations; (1) Bench top portable, (2) Palm sized portable, (3) Micro silver dollar sized implantable.   We are working on a 4th size the size of a pea.  Same circuit design.  Same signals delivered.  Just in different size configurations. 
Our single focused bioelectric stimulator platform technology is packaged in different packages with at times when needed different organ interfaces for particular applications like skin, ED, hair. It is all the same product, often times with the exact same signals, just pointed to different places on the body.
In bold short summary…
1.  We believe we have patented and developed the most advanced technology platform in the world for reversing aging and staving off aging related ailments. Patented bioelectric signals for klotho expression and patent pending licensed for klotho expressing MSCs.  Patented signals for inflammation modulation.  Patent pending signals for controlled up regulation of Sirtuins, Sestrins and NANOG powerful anti-aging and aging reversal proteins.  In short we believe we have developed technology that has potential to reverse biological age in humans by up to 5 to 20 years.
2.  We believe we have patented and developed the most effective technology platform ever developed for total and complete regeneration of organs including the heart, heart valves, aorta, lungs, brain, liver, kidney, bladder, pancreas, sexual organs, skin, hair, eyes and more.
3.  We believe our 12 issued patents and corresponding technology platform for bioelectric cancer treatment have great chance to make a major impact in providing a less toxic treatment alternative for cancer patients with a strong possibility to have higher efficacy with less side effects.
4.  We believe in 2022 we made great strides in developing technology to down regulate FABp4 and up regulate klotho to make a major dent in helping people to reverse out of both type I and type II diabetes.
5.  Five (5) of our accelerator program graduates moved out of R&D stage into commercial stage of development with FDA 510K clearances in place. SkinStim, HairCell, ErectiStim, OrthoStim and BodStim have entered a distribution and sales agreement with Lionheart Health, Inc. to launch the sales of these products in the USA and OUS markets. Sales of these products are forecasted to be over $7 million in 2023.  Shareholders of these portfolio innovation assets will now receive an 8% royalty on all full price sales and 5% on discounted sales made with quarterly disbursements pro-rata.
Below are some of our more specific progress highlights…
Intellectual property of our Portfolio Startups
(Cal-X Stars owns on average about 9% of each organ specific innovation asset with pre-emotive right to acquire up to 20% ownership right up to graduation from the accelerator program – the percentage is less for Second Heart Assist, Inc. at about 2.25% due to anti-dilution clause being waived). 
  • Over 200 new patent claims issued since 2020.
  • Over 700 new patent claims filed and pending.
  • Over 300 additional patent claims exclusively licensed.
  • Issued patent for bioelectric klotho modulation for anti-aging and muscle regeneration.
  • Patents pending for sirtuins, sestrins, NANOG anti-aging protein expressions.
  • 12 issued patents for bioelectric cancer treatment.
  • Multiple issued patents for bioelectric blood pressure control.
  • Multiple issued patents for muscle regeneration.
  • Multiple issued patents for nerve regeneration.
  • Multiple issued patents for inflammation treatment.
  • Multiple issued patents for skin regeneration.
  • Multiple issued patents for hair regeneration.
  • Multiple issued patents for sexual health and erectile dysfunction treatment.
  • Multiple issued patents for total organ regeneration including heart, liver, kidney, lungs, pancreas, brain.
  • Multiple issued patents and patents pending for heart valve regeneration.
  • Issued patent for bioelectric accelerated teeth straightening.
  • Multiple issued patents and patents pending for bone regeneration and osteointegration.
  • Multiple issued patents for bladder regeneration.
  • Multiple issued and pending patents for treating brain disorders.
  • Patents pending for bioelectric control of BDNF, serotonin and klotho up regulation and TNFa down regulation for brain treatment.
  • Multiple patents issued and pending for brain memory and cognition improvement.
  • Multiple patents issued and pending for brain depression treatment.
  • Multiple patents issued and pending for brain addiction treatment.
  • Multiple patents issued and pending for aorta regeneration.
  • Multiple patents issued and pending for kidney regeneration.
  • Multiple patents issued and pending for liver regeneration.
  • Multiple patents issued and pending for lung regeneration.
  • Multiple patents issued and pending for diabetes reversal and pancreas regeneration.
  • Patent pending for bioelectric and biologics treatment and prevention of viral infections including COVID-19.
  • Multiple patents issued and pending for treating knee osteoarthritis and other joints recovery.
  • Multiple patents issued and pending for bioelectric and biologics based vision recovery.
  • Multiple patents pending for hearting recovery.
  • Multiple patents issued and pending for treating essential tremor and Parkinson’s.
Regulatory Progress working with OEM manufacturing partners.
  • FDA 510K for improving blood circulation.
  • 2 FDA 510Ks for building and regenerating muscle.
  • FDA 510K for treating pain and inflammation.
  • FDA 510K for preventing blood clots following surgery.
  • FDA 510K for bioelectric body suit for enhancing benefits of exercises especially more rapid muscle building.
  • FDA 510K for treating arthritis including osteoarthritis.
  • IRB approvals for 8 clinical studies with more coming soon.
Finance Progress Portfolio
  • $3.7 million cash invested by Cal-X Stars shareholders has grown to over $55 million in estimated value.
  • Over $19 million in cash capital has been raised by our current portfolio of startups with more than double that also in sweat equity.
  • Valuations methodology has been confirmed by more than 5 independent 409a valuation determinations by Morgan Stanley and CARTA.
  • 5 products are being launched on the USA market this quarter with an 8% royalty coming to all innovation asset stakeholders on each sale including Cal-X Stars Business Accelerator, Inc. that holds a 9% non-dilutive ownership stake in each. These 5 products are SkinStim, HairCell, ErectiStim, BodStim and OrthoStim.
  • We finished last year about 20% under budget with $1,040,000 loss. The lions share of this funding went into accelerating and supporting portfolio R&D pre-clinical and clinical studies.
  • $115,000 of our 2022 capital came from the David Brown Fund of Washington.  All other cash capital came from convertible debt note funding provided by Leonhardt Ventures LLC.
  • About a dozen of our portfolio.stakeholders have already exited about $3 million of portfolio holdings via the FAST ACT 407 (a) 7 regulations for individual private stock sales (under this regulation sellers have to find buyers privately on their own without help from the company).
Clinical Data Progress – Positive Highlights
  • 89% of ErectiStim TM by MyoStim ED patients have achieved excellent results.  Over 100 patients enrolled so far and more enrolling now.
  • PressureStim clinical studies interim results are reporting an average of 10-20mm HG reduction in blood pressure.
  • 67% of Stem Cell Bra patients achieved breast volume enhancement with only 4 weeks of treatment 1 hour every other day.  1/3rd of treated patients experienced a full cup size increase in breast volume in just 4 weeks.
  • Approximately 40 to 60 percent of BladderCell and B-Alive patients are experiencing improvement of their bladder function with short duration non-invasive stimulation.
  • KidneyCell patients are experiencing 19 meters improvement in six minute walk on average with increased strength.
  • HairCell patients are experiencing 16.7% improvement in hair density with just 2 treatment sessions a week for 8 weeks.
  • BodStim TM and other klotho stimulation patients are experience up to 150% in circulating klohto.  More data forthcoming soon.
  • Studies have identified low klotho as a primary cause of knee osteoarthritis and OrthoStim is seeking to prove its technology can partially reverse knee osteoarthritis with klotho stimulation.
  • SkinStim treated patients in South Africa, Utah and California have achieved measurable improvements in reducing skin inflammation, higher collagen level, higher elasticity and visible reduction of facial and neck wrinkles.
  • Second Heart Assist, Inc. applied last week to being a cardio-renal syndrome heart failure study in Canada at 2 sites.  The previously completed a successful short duration pilot study in Paraguay.
Major progress was accomplished in 2022 and the plan for 2023 is clear and focused.  All serving to build greatly shareholder value.
Portfolio Group 
2022 Milestones 
2023 Plan 
Heart & Cardiovascular 
Second Heart completed transition to new cGMP manufacturer and filed EFS application. Got 21 new patent claims with USPTO.  Filed hundreds of new patent claims for multi-generational pipeline including Regenerator TM first therapeutic pump. 
BioLeonhardt launched new round of large animal studies and further developed pump and implantable stimulator. Licensed patent for klotho expressing MSCs. 
Valvublator built new simplified design test prototypes. 
PressureStim launched OUS clinical study with IRB approval. PressureStim won clinical research grant. 
Second Heart will complete 5 more large animals at GLP lab.  Will completed up to 15 CRS heart failure cases in Canada.  Will completed 10 EFS cases in USA. 
BioLeonhardt will complete 5 large animals and first in human OUS study. 
Valvublator will complete 3 large animals and first in human OUS pilot study. 
PressureStim will complete clinical studies and will file for CE mark and FDA 510K clearance. 
Brain Neuroscience 
SpineStim completed U.S. pilot study. 
DepressiStim completed pre-clinical studies and filed patent claims for BNDF, serotonin up regulation and TNFa down regulation. Filed with IRB to begin clinical studies.  Landed research grant at UCI Engineering gaining 4 Masters Engineering students of 6 months. 
Patent for bioelectric klotho issued helping all brain portfolio startups. 
2nd generation BrainBand TM design initiated. 
SpineStim launch long duration dosing study with BodStim suit. 
DepressiStim complete OUS pilot study and launch USA pivotal study. File 510K application. Complete longer dosing and longer signals 
Launch MemoryStim OUS pilot study. 
Launch TremorStim OUS pilot study. 
Complete development and testing of 2nd generation BrainBand TM design working with UCI Engineering students. 
Launch Second Brain pilot clinical study. 
Cosmetic & Personal Care 
Completed U.S. SkinStim pilot study. 
Completed U.S. HairCell pilot study. 
Filed 510K application with the FDA for OrthodontiCell 
Launched KlothoYears blood test commercially. 
Filed new patents for BMP9 bone integration based on pre-clinical data. 
Completed 2nd Stem Cell Bra clinical study. 
Filed FDA 510K pre-sub for ErectiStim TM. 
ArchStim prototypes developed and additional patent claims filed.  
BreatheStim engineering design completed.  Prototype build quote received. 
ImplantStim mouthpiece further developed and patent application prepared. 
SkinStim, HairCell, ErectiStim launching commercially on USA market via Lionheart Health, Inc. non-dilutive to their shareholders.  8% royalty on full price sales. 5% royalty on discounted sales. 
OrthodontiCell will complete U.S. pivotal clinical trial. 
Stem Cell Bra will launch pivotal  clinical study. 
ArchStim will launch pilot clinical study. 
BreatheStim will complete development of 2nd generation devices and will launch 2nd pilot clinical study. 
ImplantStim will launch pivotal clinical study. 
Major Organ Regeneration 
Completed 3rd BladderCell study OUS. 
BladderCell and B-Alive developed 2nd generation wearable design. 
Completed 2nd KidneyCell study OUS. Laid foundation for grant supported study. 
Began enrollment in 3rd EyeCell study. EyeCell one button software designed. 
PancreaCell completed pre-clinical studies and filed new patent application for diabetes reversal with FABp4 inhibition and klohto up regulation. 
OrthoStim reached out to numerous potential commercialization partners. Linked up with team in Brazil that has completed already similar clinical studies. 
BodStim TM by BIoLeonhardt Whole Body launched commercially via Lionheart Health, Inc. 
ReganLung filed patent for lung recovery in COVID-19 and other viral infection patients.  
BladderCell and B-Alive will complete clinical study with wearable  2nd generation design and will file for FDA 510K. 
KidneyCell will complete longer duration dosing study with BodStim TM. 
EyeCell will complete 3rd clinical study and will file FDA 510K application. 
PancreaCell will launch OUS clinical study for diabetes reversal. 
OrthoStim will commercially launch worldwide and will gather post market data on efficacy. 
BodStim TM will develop sales and will continue to gather post market data.  BodStim TM will develop new simpler to use software and will implement app download capability for re-occurring revenue stream forward. 
12th issued patent for bioelectric cancer treatment. 
Launching clinical studies OUS.
Will complete additional pre-clinical studies. 
2023 Big Picture FOCUSED Goals
1.  Develop sales and royalties for a full pipeline of products including SkinStim, ErectiStim, HairCell, OrthoStim, KlothoYears and BodStim via Lionheart Health, Inc.
2.  Complete pre-clinical studies and launch OUS clinical studies for BioLeonhardt and Valvublator.
3.  Move PressureStim, OrthodontiCell, BladderCell/B-Alive, TestiStim, Stem Cell Bra, DepressiStim and MemoryStim out of research stage into commercial stage.  Launch sales via Lionheart Health, Inc. or other outlets.
4.  Complete clinical studies for ImplantStim, ArchStim and BreatheStim license or sell to a commercial partner.
5.  Get 510K market clearance for portable stimulators.
6.  Get 510K market clearance for full pipeline of HTM Electronics products to be distributed by Lionheart Health, Inc. (this products reached $150 million in sales primarily in Brazil last year).
2019 through 2022 Budget and Actual (adding 2023 budget in later today)
Comparison %
Full Year 2022
Budget to Actual 
 $ 1,200,000.00   $ 900,000.00   $ 1,400,000.00   $ 1,143,411.00   $ 1,900,000.00   $ 1,039,725.00 
27.3% under
 $ 500,000.00   $ 240,000.00   $ 737,000.00   $ 619,221.00   $ 1,000,000.00   $ 655,279.05 
48% under 
Facilities – Labs, Offices All Locations but Utah
 $ 48,000.00   $ 29,000.00   $ 48,000.00   $ 51,133.00   $ 68,000.00   $ 44,968.41 
49% under
(Includes Travel, Legal Accounting, Regulatory, Quality, Insurance, Marketing, Shipping, Payroll, Tax Preparation, Patents)
 $ 355,000.00   $ 317,000.00   $ 375,000.00   $ 334,497.00   $ 400,000.00   $ 244,977.93 
37% under
Accrued Interest Loans
 $ 237,000.00   $ 276,000.00   $ 240,000.00   $ 184,299.00   $ 290,000.00   $ 184,621.00 
43% under 
Department Detail
Net Wages  $ 192,000.00   $       152,000.00   $ 282,000.00   $ 282,475.00   $ 398,000.00 
14% under 
Health Insurance  $ 12,000.00   $ 11,000.00   $ 20,000.00   $ 41,694.00   $ 52,000.00   $ 47,840.00 
9% under
Contract Labor   $ 170,000.00   $ 35,000.00   $ 50,000.00   $ 166,159.00   $ 200,000.00   $ 55,531.59     360% under 
Research Materials  $ 125,000.00   $ 32,000.00   $ 150,000.00   $ 81,224.00   $ 120,000.00 
66% under 
Dues and Subscriptions  $ 6,000.00   $ 10,000.00   $ 15,000.00   $ 11,683.00   $ 12,000.00   $ 10,341.94 
16% under
Travel  $ 55,000.00   $ 17,000.00   $ 60,000.00   $ 12,363.00   $ 60,000.00   $ 10,814.65 
553% under 
Accounting  $ 108,000.00   $ 27,000.00   $ 40,000.00   $ 44,527.00   $ 75,000.00   $ 48,960.79 
53% under
Insurance  $ 17,000.00   $ 20,000.00   $ 17,000.00   $ 23,630.00   $ 25,000.00   $ 6,549.35 
381% under
Legal Corporate  $ 50,000.00   $ 50,000.00   $ 50,000.00   $ 54,152.00   $ 50,000.00   $ 13,578.34 
368% under
Legal Patents  $ 85,000.00   $ 130,000.00   $ 150,000.00   $ 90,716.00   $ 100,000.00   $ 79,389.48 
26% under
Marketing/Conferences  $ 35,000.00   $ 19,000.00   $ 100,000.00   $ 50,531.00   $ 100,000.00   $ 33,366.00 
299% under
Payroll Fees  $ 1,100.00   $ 1,200.00   $ 1,200.00   $ 4,117.00   $ 5,000.00   $ 10,919.28 
55% over
Auto-Taxis-Uber  $ 2,600.00   $ 1,900.00   $ 1,900.00   $ 12,677.00   $ 6,700.00   $ 378.00 
1772% under
Postage & Shipping  $ 30,000.00   $ 22,000.00   $ 30,000.00   $ 14,245.00   $ 15,000.00   $ 657.75 
2280% under
Utah Lab – Leonhardt’s Launchpads Utah, Inc.
 $ 93,000.00   $ 140,000.00   $ 180,000.00   $ 175,000.00   $ 3,000.00   $ –        3000% under 
Current Estimated Valuations for each portfolio asset including value of Cal-X Stars Business Accelerator, Inc. holdings in each. 
Heart and Cardiovascular Group
Startup/LTP Price Per Share Valuation Cal-X Ownership Estimated Value No. Authorized Shares Website, Video Link or Slide Deck
Second Heart Assist, Inc. $8 $88 million $2,772,000.00 11,000,000 www.secondheartinc.com
BioLeonhardt LTP $3 $60 million $5,400,000.00 20,000,000 www.bioleonhardt.com
AortaCell LTP $1.67 $5 million $450,000.00 2,300,000 https://leonhardtventures.com/aortacell   https://vimeo.com/176895719
BioPace LTP $1 $3 million $270,000.00 3,000,000 www.bio-pace.com
Valvublator, Inc. $1 $3 million $270,000.00 3,000,000 www.valvublator.com
VibroCell LTP $2.60 $6 million $540,000.00 2,300,000 https://leonhardtventures.com/vibrocell/
 Vascustim LTP $4.34 $10 million $900,000.00 30,000,000 www.vascustim.com
PressureStim LTP $1 $5 million $450,000.00 5,000,000 www.pressurestim.com
PulseGraft, Inc. $1 $8 million $720,000.00 8,000,000 www.pulsegraft.com
Brain Group
Startup/LTP Price Per Share Valuation Cal-X Ownership Estimated Value No. Authorized Shares Website, Video Link or Slide Deck
CerebraCell LTP $4.35 $10 million $900,000.00 3,000,000 www.cerebracell.com
MemoryStim LTP $1 $3 million $270,000.00 3,000,000 www.memory-stim.com
Second Brain LTP $1 $5 million $450,000.00 5,000,000 www.secondbrainstim.com
TremorStim LTP $1 $5 million $450,000.00 5,000,000 www.tremorstim.com
SpineStim LTP $1 $5 million $450,000.00 5,000,000 www.spine-stim.com (NEW)
DepressiStim LTP $1 $5 million $450,000.00 5,000,000 www.depressistim.com (NEW)
AddictiStim LTP $1 $5 million $450,000.00 5,000,000 www.addictistim.com (NEW)
Cosmetic, Personal Care and Reproductive Health Group
Startup/LTP Price Per Share Valuation Cal-X Ownership Estimated Value No. Authorized Shares Website, Video Link or Slide Deck
TestiStim LTP $2 $20 million $1,800,000.00 10,000,000 www.testistim.com
Stem Cell Bra LTP $5 $50 million $4,500,000.00 10,000,000 www.stemcellbra.com
OrthodontiCell, Inc $8 $40 million $6,120,000.00 5,000,000 www.orthodonticell.com
DentaCell Accelerator LTP $4 $9.2 million $828,000.00 2,300,000 www.dentalcellaccelerator.com
ImplantStim LTP $1 $5 million $450,000.00 5,000,000 www.implantstim.com
ArchStim LTP $1 $8 million $720,000.00 8,000,000 www.archstim.com
BreatheStim LTP $1 $8 million $720,000.00 8,000,000 www.breathestim.com
SinusStim LTP $1 $3 million $270,000.00 3,000,000 www.sinustim.com (NEW)
HairCell LTP $5 $50 million $4,500,000.00 10,000,000 www.haircellstim.com
SkinStim LTP $5 $15 million $1,350,000.00 3,000.00 www.skin-stim.com
MyoStim ED $15 $52.5 million $4,725,000.00 3,500,000 www.erectistim.com
KlothoBios LTP $0.40 $4 million $360,000.00 10,00,000 www.klothoyears.com
Lionheart Health, Inc. $1 $15 million post money $0 15,000,000 www.lionhearthealthstim.com
Major Organ Regeneration Group
Startup/LTP Price Per Share Valuation Cal-X Ownership Estimated Value No. Authorized Shares Website, Video Link or Slide Deck
EyeCell LTP $15 $34.5 million $3,105,000.00 2,300,000 www.eye-cell.com
InStim LTP $3 $15 million $1,350,000.00 5,000.00 www.instimcell.com
PancreaCell LTP $1 $3 million $270,000.00 3,000,000 https://vimeo.com/170533425
RegenaLung LTP $2 $6 million $540,000.00 3,000,000 https://leonhardtventures.com/regenalung/
OrthoStim and Orthostim Accelerator LTP $1 $3 million $270,000.00 3,000,000 www.ortho-stim.com and www.orthostimaccelerator.com
LiverCell LTP $1.30 $3 million $270,000.00 2,300,000 www.livercellstim.com
KidneyCell LTP $1 $2.3 million $207,000.00 2,300,000 www.kidney-cell.com
EarCell LTP $1 $2.3 million $207,000.00 2,300,000 www.ear-cell.com
BioLeonhardt Whole Body – BodStim LTP $1 $30 million $2,700,000.00 30,000,000 https://vimeo.com/179280204
BladderCell LTP $5 $15 million $1,350,000.00 3,000,000 www.bladdercell.com and www.b-alivestim.com
Cancer Group
Startup/LTP Price Per Share Valuation Cal-X Ownership Estimated Value No. Authorized Shares Website, Video Link or Slide Deck
CancerCell LTP $3 $9 million $810,000.00 3,000,000 www.cancercellinc.com
Forward Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to regulatory discussions in Japan, additional sites participating in the Company’s clinical trials, the efficacy and safety of our products and therapies, preliminary conclusions about new data, the achievement of any of the anticipated upcoming milestones, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue Leonhardt Venture’s and its portfolio business and product development plans, the ability to enter into licensing and partnering arrangements, and overall market conditions. We may find it difficult to enroll patients in our clinical trials due to many factors, some of which are outside of our control. Slower than targeted enrollment could delay completion of our clinical trials and delay or prevent development of our therapeutic candidates. These forward-looking statements are made as of the date of this press release, and Leonhardt Ventures LLC, Cal-X Stars Business Accelerator, Inc., Leonhardt’s Launchpads, Lionheart Health, Inc. and our portfolio of startups assumes no obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in our PPMs and our Annual Reports under the caption titled “Risk Factors.” Leonhardt Ventures LLC, Cal-X Stars Business Accelerator, Inc, Leonhardt’s Launchpads and Lionheart Health, Inc. all expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


Howard J. Leonhardt
Leonhardt Ventures LLC
1 Kent Court
Mission Viejo, CA 92694

Brief quick elevator pitches for startups in 2017 portfolio class of Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. in order of most likely to exit soonest to latest…

2018 Likely to Be In Position for Securing Strategic Partner 
>  OrthodontiCell = Competitor Invisilign is worth $13.7 billion.  They straighten teeth in 18 months.  We can in 6 months.  They have no provision to freeze teeth straight > we do.  Current Status =  We are completing now final animal studies at Forysyth Institute in Boston and plan to enter clinical trials the 1st half of 2018 at Tufts University and UCSF in San Francisco.
>  VascuStim – Over 1 million diabetic related amputations are expected this year alone.  Over 23 million amputations are expected by 2030.   The diabetes population is exploding rising from 108 million in 1980 to 422 million in 2014 and expected to increase by 25 to 50% more by 2030.  Vascustim through collaborations has completed clinical studies in Czech Republic, Germany, Switzerland and Mexico in more than 70 patients utilizing bioelectric microcurrent stimulation and/or stem cells.  Over 30 papers have been published by a variety of teams from around the world documenting the benefits of bioelectric stimulation in improving wound healing  A separate study was completed independently by researchers in Czech Republic demonstrating the benefit of adding selected growth factors.  Our partners in Utah for amniotic fluid membranes have documented dozens of cases of diabetic leg and foot wound healing and numerous independent studies have been published documenting the same.   The VascuStim approach is to combine specific bioelectric stimulation signals for stem cell homing, blood vessel growth, healing and tissue regeneration with stem cells and selected growth factors for healing diabetic foot and leg ulcers and for limb salvage.   In some studies in some countries such as the USA we will utilize only bioelectric stimulation and amniotic fluid membranes to get started due to regulatory constraints.  Our bench top bioelectric stimulator via our manufacturing partner in California already has FDA 510K market clearance for improving blood circulation.  Amniotic fluid membranes are already marketed under the homologous exemption by our Utah based manufacturing partner.  Current Status =  We now are launching a worldwide paid registry clinical trial at more than 30 centers with us getting paid for the product during the studies under category B designation reimbursement.
>  Second Heart Assist = Competitor Abiomed is worth $7 billion.  Our pump is beating theirs so far in every performance parameter.   Our 2nd generation chronic implant is on track to be first wireless powered device with long term protection against thrombosis and hemolysis.  Current Status > We are completing now a series of large animal studies at Tufts Medical Center and plan to apply to the FDA to begin Early Feasibility Study clinical trial 1Q 2018.    We have recruited an all-star team to lead this initiative including Dr. Leslie Miller as CMO, Jeff Donofrio as President, Dr. Navin Kapur as CTO, Dr. Mark Kroll as Senior Advisor, Dr. Mark Cunninham as Chief CardioThoracic Surgery Advisor, Dr. Samer Banihani as Chief Nephrology Advisor and Dr. Nic Chronos and Dr. Jon Sherman as Cardiology Advisors.   Jane Reedy formerly from Thoratec and HeartWare has joined our team to lead Clinical and Regulatory Affairs with assistance from Larry Stevens, a former FDA reviewer, as our lead regulatory consultant and Todd Seiger as Chief Reimbursement Consultant.
>  Stem Cell Bra =  Our stem cell homing, proliferation and differentiation bioelectric bra can increase a woman’s breast fullness 30% in 4 to 6 weeks wearing the bra for only 1 hour every other day.   Over 1 billion women worldwide would be interested in acquiring a bra that increase their breast fullness safely by recruiting their own stem cells from their own fat and bone marrow with a homing signal.  Current Status > We completed one round of successful sheep studies in Argentina with histopathology examination to verify safety.  We are now are enrolling in second round of large animal studies.  We recruited Dr. Joel Aronowitz of Cedars Sinai UCLA as Chief Medical Advisor.  His team led the first ever case of stem cell repair of a cancer stricken breast in the USA with FDA clearance.
>  HairCell = Competitor Samumed using WnT signaling technology is worth $12 billion.  They get 10% hair growth.  We expect 30%.  Current Status = We are entering clinical trials in Canada and Argentina this quarter.
>  CancerCell = Competitor Novocure reached $2 billion valuation this year.  They use bioelectric signals to jam cancer tumor communication.  Our CancerCell product has 7 part bioelectric therapy for cancer including early detection of tumors, reading tumors and custom jamming communication, cell division stop signal, blood supply starving signals, surface protein expression change so body attacks tumor – immunotherapy all followed by regeneration signals.  Current Status =  We have launched translational research studies at the Pacific Neurosciences Research Institute in Santa Monica, CA.
>  BioLeonhardt = A Leonhardt team achieved 95.7 meters improvement in exercise capacity 6 minute walk testing over placebo in a Phase II/III trial of muscle stem cells alone in treating advanced heart failure at 33 leading sites the USA.  We now are applying the combination of muscle stem cells with bioelectric stimulation, selected growth factors and other agents with repeat delivery via a micro infusion pump.  We expect now over 200 meters improvement.   CRT/ICD pacers are a $9 billion industry and they achieve only 16 to 20 meters improvement.   This technology has the potential to be the first to totally regenerate failing hearts.  Current status = we are completing animal studies at University of Utah and plan to enter clinical trials in 2018 OUS.
2019 Likely to Be In Position for Securing Strategic Partner 
>  CerebraCell = Last year a Stanford team shocked the world reporting cerebracall stroke patients in wheelchairs got up and walked again after one time injections of modified stem cells to the damaged brain regions.  Our team working with the Pacific Neurosciences Institute in Santa Monica is embarking on translational research studies combining biolelectric stimulation controlled release of a stem cell homing protein with 14+ other brain regeneration promoting protein expression signals with a micro infusion pump and our CC-15 fifteen component brain regeneration composition comprised of stem cells, growth factors, amniotic fluid, selected alkaloids including tetraharmine, exosomes, Micro RNAs, nutrient hyrdogel and brain matrix.  Cerebracell has in its planned pipeline treatments not only for stroke but also for concussion, TBI, Alzheimer’s, Parkinson’s, Epilepsy and even for brain enhancement in healthy people with our Brain-N-Hance product.  Current Status > Developing a non-invasive bioelectric stimulation helmet.  Presented at Neuro Tech Leaders Forum and North Bay Innovation Summit.  Launching translational research studies at Pacific Neurosciences Institute Santa Monica.  Recruited Dr. Santosh Kesari as Chief Medical Advisor.  Developing bridges to UCLA’s Brain Institute for collaborative research.  Planning animal studies at Los Angeles Biomedical Institute and other locations.  Consulting with experts at Tufts University.   Recruited Dr. Warren Merrifield as an advisor with substantial brain diagnosis experience.   Working to file research grant applications.
> MyoStim ED – Over 322 million men worldwide suffer of erectile dysfunction.  Our bioelectric stimulation method is comprised of a simple conductive wrap connected to either a bench top or miniature bioelectric stimulator.  We believe our signals for expressing SDF-1, HGF, PDGF, VEGF, eNOS, HIF alpha, Follistatin and Tropoelastin will be more effective than other treatment options and less painful with less risk of infection the needle injections.   Current Status – We recently applied for an NIH research grant working with Dr. Nestor Gonzalez-Cadavid at Los Angeles Biomedical Research Institute that is intended to lead through translational studies in collaboration with Harbor UCLA Medical Center.
>  SkinCell Stimulator by MyoStim Skin – Well over 1 billion men and women worldwide use some product to attempt to improve the healthy youthful appearance of their facial and neck skin.   Our bioelectric stimulation method is comprised of a simple conductive mask connected to either a bench top or miniature bioelectric stimulator.  We believe our signals for expressing SDF-1, HGF, PDGF, VEGF, eNOS, HIF alpha, Follistatin and Tropoelastin will be more effective than other treatment options and less painful with less risk of infection the needle injections.   Current Status – We are in the process of launching an international clinical registry trial in multiple countries including Argentina, Canada, Mexico and Australia.
>  PancreaCell – Over 420 million worldwide suffers of diabetes.  The primary cause of diabetes is a malfunctioning pancreas exasperated by chronic inflammation.  Our PancreaCell product is designed to address both these underlying causes with a bioelectric treatment stand alone option in mild cases and a combination bioelectric + micro infusion pump + fifteen component PC-15 pancreas regeneration composition with repeat deliveries.  Current Status – We are applying to NIH in January for grant funding working with the Diabetes Research Institute at the University of Miami with Dr. Camillo Ricordi.   November of 2017 we made it to the finals of the nationwide American Diabetes Association National Innovation Pitch Contest.  We recruited Dr. Harish Kapoor as President.
>  PressureStim – Over 1.2 billion people worldwide suffer of high blood pressure.  Some estimates indicate up to 50% of all Americans suffer some form of blood pressure abnormality.  High blood pressure increases the risk of many disease states that lead to premature death.   Our team has developed a bioelectric stimulation modulation system to manage blood pressure in patients.  Current Status – Patents filed.  Searching for potential collaborative research partners in California and Utah.
>  Valvublator – Our team patented and developed the first percutaneous heart valve which today is the standard of care for hundreds for thousands of patients.   Today we have obsoleted our own invention with an even better invention.  The Valvublator helps people keep their own heart valve instead of getting an artificial or animal based implant.  The current artificial heart valve market is nearly $9 billion annually.  Cleaning, maintaining, regenerating your own heart valve is expected to open up a much larger market valued at over $15 billion annually.  The concept is to clean up and regenerate heart valves early with a catheter based procedure before the disease is so progressed that malfunction occurs.  We clean our teeth to stop plaque formation.  We need to start doing the same with our heart valves.  Our team is leading the way.   Current Status – Patents filed.  Working to build and testing first working prototypes.  Set up to do first in man studies after pre-clinical studies in Italy with Dr. Antonio Colombo.
2020 Likely to Be In Position for Securing Strategic Partner 
>  LiverCell – About 50 million people worldwide suffer of liver disease.  Our bioelectric stimulation + micro infusion pump + LC-15 fifteen component liver regeneration composition we believe can be more effective than other treatment options for liver function and health recovery.  Current Status – We recruited Ben Boytor as President.  We are working now to file research grant applications and have held some meetings with the liver regeneration team at Duke University to attempt to initiate translational research studies.
> BioPace – Over 3 million people worldwide have an implanted electronic pacemaker.  The A-Fib market is estimated to be nearly $14 billion annually.   Over 400,000 deaths annually in the USA alone are attributed to electrical heart abnormalities.   All healthy people function well with a natural biological pacemaker made up of living cells and healthy conduction cells within their heart.  BioPace has developed and has patent and patent pending a pipeline of products that utilize bioelectric signaling + stem cells + growth factors + optogenetics to restore normal pacing and electrical conduction within an ailing heart.  We believe restoring your own natural heart pacing function with living cells, the way it is built in the first place, is a far better alternative to getting a steel can with an electronic circuit board, battery and steel leads in your heart.   Current Status – Working with Dr. Alonso Moreno at the University of Utah Cardiovascular Research and Training Institute we are filing multiple research grant applications and we are building and testing prototypes as well as filing new patent claims.
>  AortaCell – Our team in the 1990’s developed and patented the first and leading endovascular stent graft system for repairing aortic aneurysms without surgery.  There are over $1 billion of annual sales of these products now worldwide.   We are not obsoleting our previous invention with AortaCell.  AortaCell utilizes bioelectric stem cell homing, proliferation and differentiation signals to repair an aortic aneurysm with living cells and living smooth muscle instead of an artificial fabric and metal implant.   Current Status – We have recruited Dr. Barry Katzen, Dr. Jacob Cynamon, Dr. Sam Ahn, Dr. Leslie Miller, Dr. Juan Parodi and Dr. Harrison Lazarus to the AortaCell team.  They are leaders in the field of aortic aneurysm repair.  We are currently building and testing prototypes and plan to begin pre-clinical animal studies soon.
>  DentaCell Accelerator – Our team is leading an innovation accelerator focused on applying our core technology platform of bioelectric stimulation + micro infusion pumps + stem cell and growth factor based compositions to dentistry.  We are combining this with a commitment to personalized, functional and holistic medicine approaches in dentistry.   Current Status – We are developing products for controlling infections, inflammation, pain and accelerated healing related to dental procedures.   We have recruited Tom Newman as President and Dr. Val Kanter as Chief Medical & Scientific Advisor.  We expect to be initiating clinical trials soon.  We have established tooth pulp banking services as our first commercial product.
> EyeCell – A number of reports have come out this year demonstrating the ability of stem cell injections to recover some forms of blindness.  We believe our product which comprises a combination of a bioelectric stimulator, which includes stem cell homing capability, a micro infusion pump and our EC-15 fifteen component eye regeneration composition can be more effective than other treatment options.  Current Status – We have completed two phases of pre-clinical studies of EyeCell in human cadaver eyes and we are now moving into animal studies at the University of Utah.  We recently received animal ethics committee approval to begin the study.
2021 Likely to Be In Position for Securing Strategic Partner 
> InStim – Noncommunicable chronic diseases such as inflammatory bowel diseases, cancer, diabetes, obesity, and pulmonary, cardiovascular, and neurodegenerative diseases are becoming the leading cause of death throughout the world. Most of these risk factors are closely linked to chronic inflammation, which leads to the development of these various chronic diseases.  Over 2 billion people worldwide suffer of some form of inflammation.  The market for anti-inflammatory drugs is expected to reach $106 billion by 2020.  InStim is the first therapy known that reads inflammation and custom delivers the precise bioelectric signals to express the precise correct anti-inflammatory or inflammatory cytokines in the proper sequence to promote optimal recovery, health and function.  The InStim microprocessor holds information on the ideal healing responses in people that recover well from an event that may trigger inflammation.  This is a baseline for custom bioelectric inflammation modulation.  Current Status – Patents filed.  Seeking out research partners to begin studies.
> CoroStim VibroCell – Blood clot, calcification and plaque formation on blood contact surfaces is a leading cause of death.   Thrombosis alone contributes to more than 52.8 million deaths annually according to the GBD.  The CoroStim VibroCell team has developed a vibrational harmonic resonance energy technology that it believes can stop blood clots, calcification and plaque from forming on both natural and artificial blood contact surfaces.  Blood clots have been the Achille’s Heel of long term circulatory assist support devices.   Current Status – Patents filed.  Building prototypes for testing.  Seeking out research collaborators.
> KidneyCell – Over 2 million people worldwide receive treatment for chronic kidney disease or failure.  1 in 10 people in the USA will afflicted with kidney disease.  Chronic kidney disease often triggers chronic inflammation which leads to multiple organ failure including heart failure.  Our team has developed a combination bioelectric stimulator + micro infusion pump + KC-15 fifteen component kidney regeneration composition for kidney regeneration and chronic inflammation treatment and management.  We believe that this therapy can be more effective than other treatment options.  Current Status – Filed patents.  Building and testing prototypes in our lab.  Seeking research collaborators to initiate translational research studies.
> BladderCell – Nearly 300 million people worldwide suffer of some sort of bladder control problem.  Our team has developed a combination bioelectric stimulator + micro infusion pump + BC-15 fifteen component bladder regeneration composition to regenerate failing bladders back to their original health and function.  Numerous independent studies have confirmed the ability for electrical stimulation and stem cell injections to improve bladder function.   Current Status – We recruited Laurelle Johnson as President.  We are building and testing prototypes in our lab.  We filed patent claims.  We are seeking out research collaborators.
> RegenaLung – Over 3 million people die each year from chronic respiratory diseases.  Recent studies have shown the strong potential for stem cell therapy to improve lung recovery including reducing chronic inflammation.  Our team has developed the first combination bioelectric stimulator + micro infusion pump + RL-15 fifteen component stem cell based lung regeneration composition therapy for lung regeneration.   Current Status – Filed patents.  Held potential research collaboration meetings with Cedars Sinai UCLA Dr. Barry Stripp, Mayo Clinic and University of Utah researchers.   Recruited Dr. Richard Koffler of Greenwings Biomedical as President.  Preparing to launch translational research studies.
>  MucosaCell – Small intestinal submucosa (SIS) is a bio-derived extracellular matrix scaffold with remarkable repairing ability for soft tissue.  Our team is working to leverage these healing properties for a variety of applications as a scaffold or hydrogel substrate.   We are also working to regenerate sub mucosa tissues throughout the body with a combination of bioelectric stimulation and repeat deliveries of the MC-15 fifteen component sub mucosa regeneration composition.  Current Status – Recruited Dr. Stuart Williams as Chief Scientific Officer and initiated research at the University of Louisville Cardiovascular Innovations Research Center.  In process of filing patents. 
2022 Likely to Be In Position for Securing Strategic Partner 
> BioLeonhardt Whole Body – This is the most ambitious research initiative of the Leonhardt team focused on whole body regeneration.  The team is planning to introduce first Bod-Stim a bioelectric body suit formed into yoga pants, pilates wear and athletic under garments to help people optimize their exercise results and recovery.   The end goal of BioLeonhardt Whole Body is the developed a body regeneration chamber that reduces aging by 30 years and extends life by 30 years by scanning the body and directing stem cell repair of organs, including inflammation management and early cancer detection and eradication with bioelectric energy and other means.   Current Status – Patents filed.  First conversations with National Science Foundation Regenerative Medicine SBIR Director about funding.  Currently building and preparing for first studies the first Bod-Stim full body suits.   Developing strategic partnerships with intelligent textile providers and other key component providers. 
>  The California Stock ExchangeTM – On path with vision to be the first social good impact stock exchange in the USA.   Following the belief that “Doing good and treating people and community well is not jus good for good sake it is good business”.   Stock exchange that only lists companies that score high on scoring system based on treating people well, having a sense of purpose, an innovation culture and treating community, health and the environment well.  Current Status –  The California Stock Exchange TM has launched the Cal-30 30 Social Good Impact Index Fund powered by Motif Investing, Cal-Xports, Cal-X MicroLoans in partnership with ZimpleMoney and KIVA, Cal-X Crowdfund Connect, Cal-X Coffee Shops and Cal-X Funders Club.   The team has registered the Trademark for The California Stock ExchangeTM and sold to NBC the TV show Crowdfund The American Dream produced by Go Go Luckey Productions and Cohen Entertainment.   Held meetings with numerous potential strategic partners including OTC Markets, TSX Toronto Venture Exchange, Startup Exchange and others.  Met with FDA SEC Commissioner Gallagher in Washington D.C.  Gave over 50 speeches at meetings on The Jobs Act, Crowdfunding and Financial Reform. 
>  Leonhardt Food & Beverage –  Vision is to sell high quality premium Lionheart and Leonhardt branded food and beverage products to raise funds for organ regeneration research by Leonhardt Ventures and Leonhardt’s Launchpads startups.  Lionheart Brands Cooperative Marketing is attempting to consolidate into one marketing initiative Leonhardt Vineyards and Lionheart Wines, Lionheart Cider, Lionheart Kombucha, Lionheart and Leonhardt Craft Beers, Lionheart Health Drinks, Lion and Lionheart coffee and other complimentary products.  Leonhardt Vineyards has experience in producing and selling over 180,000 bottles of wine to date – producing Zinfandel, Petite Syrah, Chardonnay, Sauvignon Blanc and Cabernet Sauvignon. Current Status – Developed marketing plan for Lionheart Brands and working to secure contracts with all participating producers.  Launched Food Trikes and Scooters www.foodtrikesandscooters.com and built and sold prototype units  Lucille’s American Cafe’s launched franchising program – https://leonhardtventures.com/lucilles-cafe/ = flagship restaurant in Weston, Florida is averaging over $2 million in annual sales. 
>  Kindheart Lionheart Media & Publishing – Vision is to create premier “do good, feel good” producer, creator, distributor and publisher of social good impact content.  Inspirational books, movies, TV and music that inspires people to be the best they can be.   Current Status – Launched Kindheart Lionheart TV Network – over 3 billion views across all curated programs.  Launched Kindheart Lionheart Startup Media Support Services to provide video, web site, newsletter, blog, social media, annual report , logo design, marketing and animation services to social good impact startups.   Launched a number of original TV programs = California Love, Love Dialogues, Love Roller Coaster, Covers of Great Speeches, Dolphin Smiles:  The Legend of Kindheart Lionheart.  Co-produced original short social good impact film = Melody.   
>  EarCell – Vision is to restore lost hearing with a combination of bioelectric stimulation and stem cell + growth factor infusions.  Current Status – Recently upgraded web site www.ear-cell.com  Seeking potential research collaborators.  Recruited Ken Evans as President. 
>  HeartScore – Vision is to integrate high level monitoring including bioelectric monitoring and bioelectric treatment into heart failure, inflammation and stroke management programs.  Current Status – Filed numerous patents.  Developed comprehensive program for heart, inflammation and stroke management.  Preparing for studies. 
Cal-X Stars Business Accelerator, Inc. royalty agreements for patent licenses.
  • 3% royalty on sales of MilkStim bioelectric milk stimulation products.
  • 3% royalty on sales of StimVet  veterinary products accelerator products. 
Here is a link to our Leonhardt Ventures 2017 Annual Report which is our best introduction document > http://2ho06i23weps2hx3g346udzo-wpengine.netdna-ssl.com/wp-content/uploads/2017/08/cal-x_stars_annual-report_2017_v12_web.pdf
Leonhardt’s Launchpads is the innovation and startup accelerator arm of Leonhardt Ventures founded by Howard J. Leonhardt in 1982.  Howard Leonhardt is an inventor and serial entrepreneur with 21 issued organ regeneration and recovery patents and dozens of more patent claims pending at the USPTO – https://patents.justia.com/inventor/howard-j-leonhardt.  Leonhardt Ventures has been bringing organ regeneration and recovery innovations to market since 1982.  In the 1980’s they patented and pioneered cardiovascular balloon catheter development – PolyCath.  In the 1990’s they patented and developed the leading stent graft system for endovascular repair of aortic aneurysms TALENT and the first percutaneous heart valve.  Their team completed the first ever stem cell repair of an animal heart in 1988 and landmark first-ever non-surgical stem cell repair of a human heart in 2001.  In 1999 they published their first paper on bioelectric based organ regeneration in CIRCULATION.  Leonhardt Ventures has raised over $140 million to fund its startups since its founding and has had primary exits valued at $440 million and secondary exits exceeding $4.3 billion. In 2008 they opened up their first incubator/accelerator in Northern California followed in 2013 in Southern California and 2015 in Utah.  These accelerators currently incubate 30 startups 27 of which are focused on bioelectric and endovascular based organ regeneration and recovery.   Most of the startups in the accelerator are based on Leonhardt’s patented and patent pending bioelectric stimulation platform technology for stem homing, proliferation and differentiation and organ regeneration via controlled protein expressions.   The 2017 startup portfolio is the culmination of over 35 years experience in organ regeneration and recovery research and experimentation. 
Our accelerator business model is to advance each startup to first-in-man results and then sell to a strategic partner/buyer preferably with a 3% royalty forward on net sales.   Our goal is 23X ROI on accelerator shares and 63X on individual startup shares after 5 years.  See schedule chart below of expected exits timing over the next 5 years. 
Investments at this time are all 2:1 meaning if you invest $30,000 in the innovation accelerator you receive $30,000 worth of shares of the accelerator stock AND also a 2:1 a warrant valued at $30,000 to acquire at no further charge $30,000 worth of shares of any or all of the 30 startups in the 2017 accelerator portfolio class– https://leonhardtventures.com/our-companies/#toggle-id-1  You have until Dec. 31st of the year you invest to decide your allocation of your warrant to any or all of the startups you choose. 
The startups generally are owned as follows = 50.1% owned by Leonhardt Ventures LLC, 9 to 20% owned by Cal-X Stars Business Accelerator, Inc. DBA Leonhardt’s Launchpads and the balance 29.9% to 40.9%  owned by management, advisors and outside shareholders.  The startups generally start out with a valuation of $2.3 to $5 million and the target goal is to sell them in 5 years or after first-in-man data comes in, which ever comes first, at $240 to $800 million with ideally a 3% royalty on net sales forward.   We strive as a goal to keep dilution to 37% over 5 years with our anti-dilutive business model. 
Slide Deck from Annual Shareholder Meeting May 2017 > https://app.slidebean.com/p/j1hvREqfeg/Leonhardt-MedVentures-SPV-Copy-Copy
Here are the current valuations and shares prices for each startup in our accelerators in California and Utah  https://leonhardtventures.com/our-companies/#toggle-id-2
Product Groups:
1. Heart & Cardiovascular.
2. Brain.
3. Cosmetic & Personal Care.
4. Cancer.
5. Regenerative Economy. 
Our fall 2016 Newsletter has convenient links to all our videos for each startup in once place >  – http://eepurl.com/cn39Kv   
Here is a link to photos and bios of our team members >https://leonhardtventures.com/team/ 
Our Scientific Advisory Board > https://calxstars.com/scientific-advisory-board/
Attached are updated Executive Summaries for Cal-X Stars Business Accelerator, Inc. DBA Leonhardt’s Launchpads. 
Top 6 startups in our accelerator ripe for finding a strategic buyer in 2018….
1.  OrthodontiCell > completing animal studies now at Forsyth Institute moving to clinical studies at Tufts and UCSF. 
2.  VascuStim > completed pilot clinical studies with success now moving to large registry clinical trial. 
3.  Second Heart Assist, Inc. > completed Phase I large animal studies moving to Phase II in November and hope to be in clinical studies early next year. 
4.  Stem Cell Bra > completed Phase I sheep studies with success now moving to Phase II studies. 
5.  HairCell > launching clinical trials in Canada, Argentina and Mexico. 
6.  BioLeonhardt > completing two animal studies in Utah. 

Top 6 startups in our accelerator ripe for finding a strategic partner/buyer in 2019..

1.  CancerCell > launching lab and animal studies with Pacific NeuroSciences Center in Los Angeles and Harbor UCLA.
2.  CerebraCell > launching lab and animal studies with Pacific NeuroSciences Center in Los Angeles and Harbor UCLA.
3.  MyoStim ED > just applied for NIH grant with UCLA. 
4.  SkinCell Stimulator by MyoStim Skin > preparing to launch clinical studies OUS. 
5.  PancreaCell > preparing for grant applications with U of Miami Diabetes Research Institute. 
6.  PressureStim > just filed patent application. 

Top 6 startups in our accelerator ripe for finding a strategic partner/buyer in 2020…

1.  Valvublator > preparing to build test prototypes with Biomerics. 
2.  LiverCell > preparing for animal studies at Duke University. 
3.  BioPace > filed NIH grant application with U of Utah.  Preparing new applications. 
4.  AortaCell > filed patent application. 
5.  DentaCell > preparing numerous studies.  Meeting next Thursday with investigator Los Angeles .
6.  EyeCell > completing animal studies at U of Utah with partial grant support. 

Top 6 startups in our accelerator ripe for finding a strategic partner/buyer in 2021 

1.  InStim > filed patent application. 
2.  CoroStim VibroCell > filed patent application.  Building prototypes. 
3.  KidneyCell > filed patent application. 
4.  BladderCell > seeking out research partners. 
5. RegenaLung ECMOCath and COPD > seeking out research partners. 
6. MucosaCell > launching research at U of Louisville. 

Top 6 startups in our accelerator ripe for finding a strategic partner/buyer in 2022

1.  BioLeonhardt Whole Body > applying for NSF SBIR grant application. 
2.  The California Stock ExchangeTM > met with TSX Toronto Venture Exchange about partnership working to close.  
3.  Leonhardt Food & Beverage > preparing cooperative marketing launch. 
4.  Kindheart Lionheart Media & Publishing > preparing ad sales launch. 
5.  EarCell > filed patent application.  Seeking research partners. 
6.  HeartScore > filed patent application.  Seeking research partners. 
Our Scientific Advisory Board > https://calxstars.com/scientific-advisory-board/
Here are profiles of Dr. Mark Kroll, Dr. Navin Kapur, Dr. James W. Kronberg, Dr. John Langell and Dr. Ron Waksman the latest additions to our team…

The Idea Man | Minnesota Business Magazine

With over 300 patents, mark Kroll leads the market on medical device design. … As one of the most prolific inventors of medical devices in the world, Dr. Mark Kroll, retired chief technology officer and senior vice president from St. Jude Medical, knows what it means to improve …


Navin Kapur | Professional Profile – LinkedIn

View Navin Kapur’s profile on LinkedIn, the world’s largest professional community. Navin’s experience … Summary. Dr. Kapur is an Associate Professor in the Department of Medicine. … Director, CardiacBiology Research Center (CBRC).


James W. Kronberg Inventions, Patents and Patent … – Justia Patents

James W. Kronberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have …


John Langell, MD, PhD, MPH, MBA, FACS | Professional Profile

Salt Lake City, Utah – ‎–UNIVERSITY LEADERSHIP AND HEALTHCARE EXECUTIVE | Large Institutional Leadership | Innovation | Quality Improvement – ‎Xenocor

John Langell, MD, PhD, MPH, MBA, FACS … View John’s Full Profile … of the University of Utah School of Medicine in Salt Lake City, where I drive almost two dozen …. Center for Medical Innovation | University of Utah Health Sciences Center, …


Ron Waksman – MedStar Health Research Institute

Jan 23, 2015 – Ron Waksman, MD, FACC, is Associate Director, Division of Cardiology … Dr. Waksman has authored/co-authored 310 published manuscripts and … of the annual Cardiovascular Revascularization Therapies (CRT) meeting, …

Here are some big milestones coming up…
>  Second Heart presentation at TCT Denver last week of October 2017
>  Second Heart Phase II large animal study at Tufts Medical Center Boston completed first week of November.
>  Second Heart FDA filing pre-submission for Early Feasibility Study.  Set to meet FDA Jan. 16th in D.C.
>  Second Heart USTAR $170,000 grant award for 2nd gen. wireless device development.
>  New Caltech patent license.
>  BioLeonhardt  heart regeneration completing small and large animal studies at U of Utah with grant support $300,000.
>  BioLeonhardt heart regeneration filing grant application with Texas Heart Institute Dr. Doris Taylor.
>  VascuStim diabetic foot ulcer treatment launching clinical registry study worldwide bioelectric + amniotic fluid membranes.
>  Valvublator heart valve decalcification and regeneration – building out first test prototypes.
>  VibroCell vibrational energy device for preventing blood clots.  Patent app is filed.  Building out test prototypes soon.
>  Launching translational studies at Pacific Neurosciences Institute and LABiomed Harbor UCLA Los Angeles.
>  Filing new patent application for concussion.
>  Phase II large animal studies for Stem Cell Bra breast tissue generation in Argentina.
>  OrthdontiCell moving into definitive animal studies at Forsyth Institute Boston.
>  OrthdodontiCell preparing for first-in-man studies at Tufts University and UCSF San Francisco.
>  HairCell heart regeneration clinical studies launch in Argentina and Canada.
>  DentaCell bioelectric and stem cell dental products innovation accelerator launch.
>  SkinCell Stimulator by MyoStim Skin is preparing for OUS first-in-man studies.
>  Completing EyeCell eye regeneration studies at U of Utah with partial grant support.
>  Filing bioelectric inflammation control patents.
>  CancerCell  is launching translational studies at Pacific NeuroSciences Institute and John Wayne Cancer Institute Santa Monica, CA.
>  Filing new bioelectric cancer patents for CancerCell to add to already large estate in area.
>  The California Stock ExchangeTM is working to close agreement with potential strategic partners.
>  Hiring ad Sales Manager for Kindheart Lionheart TV Network.
>  Launching Lionheart Brands Cooperative Marketing.


Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc.,  12655 W Jefferson Blvd, Los Angeles, CA 90066
Leonhardt’s Launchpads Utah, Inc. 370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ 2500 S State St. #224, Salt Lake City, UT 84115

Welcome to CalxStars

We work with founders on their ideas, as well as conceive our own ideas in-house – then we assemble talent and teams to create new companies. We start with analyzing each company thoroughly and we provide a 15 page report identifying strengths and weaknesses. The report concludes with a Probability of Survival Score. Based on this analysis we provide to the company a 5 year mentoring and funding road map.